Neoadjuvant PD-1 blockade with toripalimab, with or without celecoxib, in mismatch repair-deficient or microsatellite instability-high, locally advanced, colorectal cancer (PICC): a single-centre, parallel-group, non-comparative, randomised, phase 2 trial

医学 微卫星不稳定性 塞来昔布 结直肠癌 临床终点 内科学 肿瘤科 癌症 胃肠病学 封锁 临床试验 生物 微卫星 受体 生物化学 等位基因 基因
作者
Huabin Hu,Liang Kang,Jianwei Zhang,Zehua Wu,Hui Wang,Meijin Huang,Ping Lan,Xiaojian Wu,Chao Wang,Wuteng Cao,Jiancong Hu,Yan Huang,Liang Huang,Huaiming Wang,Lishuo Shi,Yue Cai,Cailu Shen,Jiayu Ling,Xiaoyu Xie,Yonghua Cai
出处
期刊:The Lancet Gastroenterology & Hepatology [Elsevier]
卷期号:7 (1): 38-48 被引量:199
标识
DOI:10.1016/s2468-1253(21)00348-4
摘要

Background PD-1 blockade is highly effective in patients with mismatch repair-deficient or microsatellite instability-high metastatic colorectal cancer. The role of single-agent PD-1 blockade in the neoadjuvant setting for resectable mismatch repair-deficient or microsatellite instability-high colorectal cancer remains unclear. We investigated the efficacy and safety of PD-1 blockade with toripalimab, with or without the COX-2 inhibitor celecoxib, as neoadjuvant treatment for mismatch repair-deficient or microsatellite instability-high, locally advanced, colorectal cancers. Methods The PD-1 Inhibitor in Microsatellite Instability Colorectal Cancer (PICC) trial was a single-centre, open-label, parallel-group, non-comparative, randomised, phase 2 study undertaken at the Sixth Affiliated Hospital of Sun Yat-sen University (Guangzhou, China). Eligible patients were aged 18–75 years, had histologically confirmed mismatch repair-deficient or microsatellite instability-high colorectal cancer, had clinical stage T3–T4 or any T with lymph node positivity (N+), Eastern Cooperative Oncology Group performance score of 0 or 1, and adequate haematological, hepatic, and renal function. Participants were randomly assigned (1:1), without any stratification or balanced blocking, to receive toripalimab 3 mg/kg intravenously on day 1, with or without celecoxib 200 mg orally twice daily from day 1 to 14 of each 14-day cycle, for six cycles before surgical resection. Adjuvant treatment with toripalimab with or without celecoxib was permitted at the investigators' discretion. The primary endpoint was the proportion of patients with pathological complete response, defined as tumours without any viable tumour cells in the resected primary tumour sample and all sampled regional lymph nodes. All efficacy and safety analyses were assessed in the modified intention-to-treat population, which included all patients who were randomly assigned to treatment and who received at least one dose of toripalimab. This trial is registered with ClinicalTrials.gov, NCT03926338, and is ongoing. Findings Between May 1, 2019, and April 1, 2021, 53 patients were screened, of whom 34 were randomly assigned to either the toripalimab plus celecoxib group (n=17) or the toripalimab monotherapy group (n=17). As of data cutoff (Aug 10, 2021), median follow-up was 14·9 months (IQR 8·8–17·0). All patients received study treatment and underwent surgical resection; there were no treatment-related surgical delays. All 34 patients had an R0 resection (>1 mm resection margin). 15 of 17 patients (88% [95% CI 64–99]) in the toripalimab plus celecoxib group and 11 of 17 patients (65% [38–86]) in the toripalimab monotherapy group had a pathological complete response. All patients continued to receive adjuvant toripalimab with or without celecoxib for a total perioperative duration of 6 months and were alive and free of recurrence at data cutoff. During neoadjuvant treatment, ten (59%) patients in the toripalimab plus celecoxib group and ten (59%) in the toripalimab monotherapy group had grade 1–2 treatment-related adverse events. Only one (3%) of 34 patients, who was in the toripalimab plus celecoxib group, had a grade 3 or higher treatment-related adverse event during the neoadjuvant phase, which was grade 3 increased aspartate aminotransferase levels. In the adjuvant phase, only one (3%) of 34 patients, who was in the toripalimab monotherapy group, had a grade 3 or higher treatment-related adverse events, which was grade 3 increased aspartate aminotransferase and alanine aminotransferase levels. Interpretation Neoadjuvant toripalimab with or without celecoxib could be a potential therapeutic option for patients with mismatch repair deficient or microsatellite instability-high, locally advanced, colorectal cancer. This treatment was associated with a high pathological complete response rate and an acceptable safety profile, which did not compromise surgery. Longer term follow-up is needed to assess effects on survival-related endpoints. Funding The National Key R&D Program of China, the National Natural Science Foundation of China, and the Chinese Society of Clinical Oncology-Junshi Biosciences Oncology Immunity Research. Translation For the Chinese translation of the abstract see Supplementary Materials section.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
量子星尘发布了新的文献求助10
4秒前
李爱国应助大橙子采纳,获得10
5秒前
magictoo发布了新的文献求助30
11秒前
13秒前
yang完成签到,获得积分10
13秒前
Minicoper发布了新的文献求助10
14秒前
快乐丸子完成签到,获得积分10
15秒前
简单而复杂完成签到,获得积分10
15秒前
大橙子发布了新的文献求助10
19秒前
张牧之完成签到 ,获得积分10
21秒前
冷冷暴力完成签到,获得积分10
23秒前
YYY完成签到,获得积分10
23秒前
23秒前
gujian完成签到 ,获得积分10
26秒前
帅气的秘密完成签到 ,获得积分10
27秒前
自然函发布了新的文献求助10
31秒前
冰冰双双完成签到,获得积分10
31秒前
开心夏旋完成签到 ,获得积分0
33秒前
我要读博士完成签到 ,获得积分10
36秒前
活泼的大船完成签到,获得积分10
36秒前
AFF完成签到,获得积分10
37秒前
38秒前
无私小小完成签到,获得积分10
39秒前
随心所欲完成签到 ,获得积分10
40秒前
润润轩轩完成签到 ,获得积分10
41秒前
CodeCraft应助大橙子采纳,获得10
41秒前
ZR完成签到,获得积分10
42秒前
magictoo完成签到,获得积分10
42秒前
陈昊发布了新的文献求助10
43秒前
zhangliangfu完成签到 ,获得积分10
43秒前
金石为开完成签到,获得积分10
43秒前
王QQ完成签到 ,获得积分10
45秒前
唐唐完成签到 ,获得积分10
49秒前
最棒哒完成签到 ,获得积分10
49秒前
鸣鸣完成签到,获得积分10
50秒前
123321完成签到 ,获得积分10
51秒前
卓若之完成签到 ,获得积分10
52秒前
苯二氮卓完成签到,获得积分10
53秒前
温暖完成签到 ,获得积分10
55秒前
mojomars完成签到,获得积分10
55秒前
高分求助中
【提示信息,请勿应助】关于scihub 10000
Les Mantodea de Guyane: Insecta, Polyneoptera [The Mantids of French Guiana] 3000
徐淮辽南地区新元古代叠层石及生物地层 3000
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
Handbook of Industrial Diamonds.Vol2 1100
Global Eyelash Assessment scale (GEA) 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 550
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 4038128
求助须知:如何正确求助?哪些是违规求助? 3575831
关于积分的说明 11373827
捐赠科研通 3305610
什么是DOI,文献DOI怎么找? 1819255
邀请新用户注册赠送积分活动 892655
科研通“疑难数据库(出版商)”最低求助积分说明 815022